Advertising disclosure — We may earn a commission if you start care through some of these links, at no extra cost to you. How we're funded.
Guides · 29 in the library · 147 cited sources
The women's-health angle on GLP-1.
PCOS and insulin resistance, the perimenopause transition, the menstrual cycle, labs and contraception — the questions a general GLP-1 guide skips. Looking for a specific program instead? Read the provider reviews.
Start here
GLP-1 Medication and PCOS: What Women Should Know
How GLP-1 medicines target the insulin resistance behind PCOS weight — and the questions to ask a provider about tirzepatide, labs and androgens.
Read the guide →4 cited sourcesWhere the guides point
See all 80 ranked →The three highest-placed programs on the Luna Fit Score, our women's-health rubric.
- A93Visit
Strongest: Price transparency 97
$99/moTop fitAll 50 statesTirzepatide priced - A−92Visit
Strongest: Nationwide access 95
$249 every 4 weeks month-to-month (13 charges a year); $212/mo only on the 12-month prepayAll 50 statesTirzepatide priced - B+88Visit3.
Eden
Strongest: Nationwide access 95
Assume any provider we list may compensate us — we may earn a commission if you start care through some of these links, at no extra cost to you. See our disclosure.
The rest of the library
GLP-1 Care Through Perimenopause and Menopause
The midlife metabolic shift is real. How GLP-1 medicines fit alongside the hormonal changes of the menopause transition — and what to weigh.
4 cited sources
GLP-1 Medicines, Your Cycle, and Contraception
Appetite, the menstrual cycle, birth control absorption and pregnancy — the women's-specific questions worth raising before you start a GLP-1.
4 cited sources
How to Choose a GLP-1 Provider as a Woman
A women's-health checklist for picking a GLP-1 provider: hormonal suitability, labs, clinical oversight and price — not just the cheapest vial.
4 cited sources
Compounded vs Brand-Name GLP-1 for Women
What the compounded-vs-brand choice really means for women: what the evidence covers, what compounding is, and how to decide with a clinician.
5 cited sources
Semaglutide vs Tirzepatide for Women: Insulin Resistance and Results
How semaglutide and tirzepatide compare for women — mechanism, weight-loss results and why insulin resistance shapes the choice.
4 cited sources
GLP-1 and Insulin Resistance: Why It Matters for Women
The metabolic mechanism behind stubborn weight in women — how insulin resistance works and where GLP-1 medicines act on it.
4 cited sources
What GLP-1 Costs and How to Start Safely
A measured women's-lens look at GLP-1 cost and starting safely: 503A vs 503B pharmacies, LegitScript, FDA compounding and what to verify.
3 cited sources
Labs and Monitoring on GLP-1: What Women Should Ask For
A women's-health guide to labs and monitoring on GLP-1: which markers matter, why oversight counts, and what to ask a provider to track.
4 cited sources
GLP-1 Medications and Birth Control: What Women Need to Know
Does a GLP-1 affect your birth control? Why tirzepatide can lower the pill's reliability, semaglutide differs, and the fertility catch behind Ozempic babies.
11 cited sources
GLP-1 Hair Loss in Women: What's Actually Causing the Shedding
Shedding on a GLP-1 is usually not one thing. How to tell medication-linked hair loss from perimenopausal thinning, PCOS, and low ferritin.
6 cited sources
GLP-1 and Muscle Loss in Women: What Midlife Changes
Some lean mass goes with any weight loss. Why midlife stacks that on a decline already underway — and what the evidence in women actually supports.
7 cited sources
GLP-1 Medication and Bone Density: What Women Should Know
A GLP-1 trial in adults with fracture risk found lower hip and spine bone density at 52 weeks. What that means layered onto menopausal bone loss.
6 cited sources
GLP-1 Medication and Breastfeeding: What the Evidence Actually Shows
The FDA label treats the semaglutide tablet and injection differently for breastfeeding. What the new human milk data shows, and what it doesn't yet.
6 cited sources
GLP-1 Medication and Gallstones: Why Women Start From Higher Risk
GLP-1s raise gallbladder disease risk most in weight-loss trials specifically. Why estrogen already puts women 2-3x higher than men, and the symptoms to know.
6 cited sources
GLP-1 Medication and Thyroid Conditions: What Women Should Know
The label warning about thyroid tumors is not the same question as Hashimoto's or hypothyroidism, which affect women far more. What actually matters for each.
7 cited sources
GLP-1 Medication and Breast Cancer: History, Risk, and the Evidence
Obesity is a real, established risk factor for postmenopausal breast cancer. What new survivor data on GLP-1 use shows — and what questions remain open.
7 cited sources
GLP-1 Medication and Eating Disorder History: What to Ask Before You Start
GLP-1s show real promise for binge eating disorder — and the same appetite suppression can reinforce restriction in a history of anorexia. What to ask.
5 cited sources
GLP-1 Medication, Migraine, and Intracranial Hypertension in Women
IIH is a condition that affects almost exclusively women — and a randomized trial found a GLP-1 lowered intracranial pressure directly. What the evidence shows.
8 cited sources
GLP-1 Medication and Autoimmune Disease: RA and Lupus in Women
Rheumatoid arthritis and lupus both skew heavily female. What early evidence shows about GLP-1 medication and disease activity — and what remains unproven.
8 cited sources
GLP-1 Medication Before IVF and Fertility Treatment: What to Know
Weight loss before IVF is often recommended, but a GLP-1 raises real timing questions around egg retrieval and embryo transfer. What the evidence shows.
7 cited sources
GLP-1 Medication and Heart Disease Risk in Women
Semaglutide's landmark cardiovascular trial enrolled a population that was 72.5% male. What that means for how much the results actually tell women.
6 cited sources
The Edit Review: $209 Semaglutide, Cancel Anytime
The Edit's semaglutide and tirzepatide ladder is the only one of seven we could not break on arithmetic. What we verified in August 2026, and what we could not.
3 cited sources
Pepti Review: $99 Semaglutide and a Ladder That Contradicts It
Pepti renders $99 semaglutide flat at every dose — while its own production data carries a per-dose ladder up to $449. We could not break the tie. Here is why.
3 cited sources
Trellis Vitality Review: One Complete Table, Four Blanks
Trellis publishes the best-formed GLP-1 price table of seven providers we screened — and four other programs with no ladder at all. Verified August 2026.
5 cited sources
Auren Rx Review: A Real Monthly Rung, an Unpublished Map
Auren Rx prints an explicit no-commitment rung on every product — then never says which states it serves. What we verified in August 2026, and the two traps.
2 cited sources
Vyvron Review: Thirteen Charges a Year, Not Twelve
Vyvron bills every four weeks while printing '/mo', and has no monthly tirzepatide plan at all. The arithmetic, the disclosures it gets right, August 2026.
3 cited sources
Rehydra+ Wellness Review: Six Months, No Way Out
Every Rehydra+ GLP-1 membership is a six-month non-cancelable contract. The advertised $119/mo is really $714 committed. What we verified in August 2026.
2 cited sources
Lighter You Review: A Real Operator With No Public Price
Lighter You names four pharmacies with street addresses and publishes no price you can verify. Its $99 headline buys nothing. What we found in August 2026.
3 cited sources
Guides are educational and cite primary research where a claim is clinical. Not medical advice — see our medical disclaimer.